Key considerations for biosimilar use in managing bone health.
EP. 1: Optimizing Biosimilar Treatment Strategies in Bone Health
Colin C. Edgerton, MD, discusses key considerations for utilizing biosimilars in the bone health treatment landscape.
EP. 2: Managing Treatment Strategies for Osteoporosis Amid Evolving Biologic and Biosimilar Landscape
Jeffrey Curtis, MD, MS, MPH, provides expert perspective for navigating the evolving treatment landscape of osteoporosis and key considerations for biologic and biosimilar utilization.
The Top 5 Biosimilar Articles for the Week of March 24
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount
Adalimumab Biosimilars Show Similar Outcomes in Psoriasis After Nonmedical Switch
